Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: the phase 3 randomized SUNLIGHT study

被引：0
|
作者：
Modest, D. P. [1 ]
Tabernero, J. [2 ]
Prager, G. [3 ]
Fakih, M. [4 ]
Ciardiello, F. [5 ]
Van Cutsem, E. [6 ,7 ]
Elez, E. [2 ]
Cruz, F. [8 ]
Wyrwicz, L. [9 ]
Stroyakovskiy, D. [10 ]
Papai, Z. [11 ]
Poureau, P. -G. [12 ]
Liposits, G. [13 ]
Cremolini, C. [14 ]
Benhadji, K. [15 ]
Bondarenko, I. [16 ]
Skanji, D. [17 ]
Roby, L. [17 ]
Amellal, N. [17 ]
Taieb, J. [18 ]
机构：
[1] Charite, Hamatol Onkol & Tumorimmunol, Berlin, Germany
[2] Vall dHebron Univ Hosp & Inst Oncol VHIO, UVic UCC, IOB Quiron, Barcelona, Spain
[3] Med Univ Vienna, Dept Med 1, Vienna, Austria
[4] City Hope Comprehens Canc Ctr, Duarte, CA USA
[5] Univ Campania Luigi Vanvitelli, Dept Precis Med, Neapel, Italy
[6] Univ Hosp Leuven, Dept Digest Oncol, Herent, Belgium
[7] Katholieke Univ Leuven, Dept Digest Oncol, Herent, Belgium
[8] Nucleo Pesquisa & Ensino Rede Sao Camilo, Sao Paulo, Brazil
[9] Maria Sklodowska Curie Natl Canc Res Inst, Dept Radiotherapy & Oncol, Warsaw, Poland
[10] Moscow City Oncol Hosp 62, Moscow, Russia
[11] Duna Med Ctr, Med Oncol, Budapest, Hungary
[12] Inst Cancerol, Brest, France
[13] Univ Southern Denmark, Dept Clin Res, Odense, Denmark
[14] Univ Pisa, Dept Translat Res & New Technol, Pisa, Italy
[15] Taiho Oncol Inc, Princeton, NJ USA
[16] Dnipropetrovsk Med Acad, Dept Oncol & Med Radiol, Dnipro, Ukraine
[17] Servier Int Res Inst, Suresnes, France
[18] Univ Paris Cite, Georges Pompidou European Hosp, SIRIC CARPEM, Paris, France
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V1019
引用
收藏
页码：157 / 158
页数：2
相关论文
共 50 条
  • [21] First-line trifluridine/tipiracil plus bevacizumab for unresectable metastatic colorectal cancer: SOLSTICE study design
    Andre, Thierry
    Saunders, Mark
    Kanehisa, Akira
    Gandossi, Eric
    Fougeray, Ronan
    Amellal, Nadia Causse
    Falcone, Alfredo
    FUTURE ONCOLOGY, 2020, 16 (04) : 21 - 29
  • [22] Cost-effectiveness analysis of trifluridine/tipiracil combined with bevacizumab vs. monotherapy for third-line treatment of colorectal cancer
    Huang, Long-Zhuan
    Chen, Ya-Qing
    Gu, Hang-Ye
    Chen, Yong
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [23] Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
    Kotani, Daisuke
    Kuboki, Yasutoshi
    Horasawa, Satoshi
    Kaneko, Asumi
    Nakamura, Yoshiaki
    Kawazoe, Akihito
    Bando, Hideaki
    Taniguchi, Hiroya
    Shitara, Kohei
    Kojima, Takashi
    Tsuji, Akihito
    Yoshino, Takayuki
    BMC CANCER, 2019, 19 (01)
  • [24] Biomarker analysis using plasma angiogenesis factors in the TRUSTY study: A randomized phase 2/3 study of trifluridine/ tipiracil plus bevacizumab as second-line treatment for metastatic colorectal cancer
    Taniguchi, H.
    Kuboki, Y.
    Watanabe, J.
    Terazawa, T.
    Kawakami, H.
    Yokota, M.
    Nakamura, M.
    Kotaka, M.
    Sugimoto, N.
    Ojima, H.
    Oki, E.
    Kajiwara, T.
    Moriwaki, T.
    Takayama, T.
    Denda, T.
    Tamura, T.
    Sunakawa, Y.
    Ishihara, S.
    Nakajima, T.
    Morita, S.
    Shirao, K.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S365 - S365
  • [25] Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
    Daisuke Kotani
    Yasutoshi Kuboki
    Satoshi Horasawa
    Asumi Kaneko
    Yoshiaki Nakamura
    Akihito Kawazoe
    Hideaki Bando
    Hiroya Taniguchi
    Kohei Shitara
    Takashi Kojima
    Akihito Tsuji
    Takayuki Yoshino
    BMC Cancer, 19
  • [26] Health-related quality of life associated with trifluridine/tipiracil in combination with bevacizumab in refractory metastatic colorectal cancer: An analysis of the phase 3 SUNLIGHT trial
    Prager, G.
    Taieb, J.
    Fakih, M.
    Ciardiello, F.
    Van Cutsem, E.
    Elez, E.
    Cruz, F.
    Wyrwicz, L.
    Stroyakovskiy, D.
    Papai, Z.
    Poureau, P.
    Liposits, G.
    Cremolini, C.
    Bondarenko, I.
    Modest, D.
    Amellal, N.
    Hassan, H.
    Skanji, D.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S184 - S184
  • [27] Exploratory analysis of baseline tumor burden in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer
    Masuishi, Toshiki
    Kuboki, Yasutoshi
    Terazawa, Tetsuji
    Nakamura, Masato
    Watanabe, Jun
    Ojima, Hitoshi
    Makiyama, Akitaka
    Kotaka, Masahito
    Hara, Hiroki
    Ohta, Takashi
    Oki, Eiji
    Sunakawa, Yu
    Ishihara, Soichiro
    Taniguchi, Hiroya
    Nakajima, Takako Eguchi
    Morita, Satoshi
    Shirao, Kuniaki
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [28] Randomized study evaluating trifluridine/tipiracil (TAS-102) versus + trifluridine/tipiracil plus bevacizumab as last-line therapy in patients with chemorefractory unresectable metastatic colorectal cancer (mCRC).
    Pfeiffer, Per
    Yilmaz, Mette
    Moller, Soren
    Maltha, Line
    Krogh, Merete
    Zitnjak, Daniela
    Szameitat, Caroline Lemb
    Hejlesen, Finn
    Thomsen, Karina Gravgaard
    Qvortrup, Camilla
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [29] Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study
    Signorelli, Carlo
    Calegari, Maria Alessandra
    Basso, Michele
    Anghelone, Annunziato
    Lucchetti, Jessica
    Minelli, Alessandro
    Angotti, Lorenzo
    Zurlo, Ina Valeria
    Schirripa, Marta
    Chilelli, Mario Giovanni
    Morelli, Cristina
    Dell'Aquila, Emanuela
    Cosimati, Antonella
    Gemma, Donatello
    Ribelli, Marta
    Emiliani, Alessandra
    Corsi, Domenico Cristiano
    Arrivi, Giulia
    Mazzuca, Federica
    Zoratto, Federica
    Morandi, Maria Grazia
    Santamaria, Fiorenza
    Saltarelli, Rosa
    Ruggeri, Enzo Maria
    CURRENT ONCOLOGY, 2023, 30 (06) : 5456 - 5469
  • [30] Predictive marker for response to trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer patients
    Takahashi, Toshiaki
    Shigeyasu, Kunitoshi
    Kondo, Yoshitaka
    Takeda, Sho
    Umeda, Hibiki
    Moriwake, Kazuya
    Kayano, Masashi
    Sakurai, Yuya
    Nakamura, Shunsuke
    Takahashi, Masafumi
    Nitta, Kaori
    Yoshida, Kazuhiro
    Matsumi, Yuki
    Michiue, Hiroyuki
    Yamamoto, Hideki
    Kishimoto, Hiroyuki
    Teraishi, Fuminori
    Shoji, Ryohei
    Kanaya, Nobuhiko
    Kashima, Hajime
    Kakiuchi, Yoshihiko
    Kuroda, Shinji
    Kagawa, Shunsuke
    Fujiwara, Toshiyoshi
    BMC CANCER, 2025, 25 (01)
12345